Skip to content
Buy This GLP
← Research
Evidence

Eating Behavior Changes on Five Obesity Drugs: A 66-Patient Brazilian Study

A Brazilian clinic scored five eating-behavior domains before and after six months on five obesity medications. The effect sizes are large, and the analyzed cohort was 66 early responders.

Editorial profile: Carla MedinaBuy This GLP Editorial Team6 min read
Selected within-group effect sizes (Cohen’s dᶻ)Tirzepatide, pleasure-driven eating2.06Naltrexone/bupropion, emotional eating2.04Semaglutide, emotional eating1.5266 early responders across five medication groups

A São Paulo team measured changes in five eating behaviors after six months of treatment (n = 66) [1]. The scale asked about habits such as eating for pleasure or in response to emotion. That differs from studies on intrusive thoughts about food, which look at how often thoughts about eating occupy someone’s attention. Both approaches rely on what participants report.

What changed in the questionnaire?

The largest reported reduction in pleasure-driven eating was in the tirzepatide group (Cohen’s dᶻ = 2.06). The reported change in emotional eating was 2.04 in the naltrexone/bupropion group and 1.52 in the semaglutide group [1]. These are standardized changes within each treatment group. They are neither percentages nor estimates of how much better one medication worked than another.

Can the scores guide treatment selection?

The study was retrospective, with no randomized assignment or untreated group. Research on why weight loss varies on GLP-1 treatment puts this cohort in context. The study could describe how early responders’ ratings changed, but it could not predict response from a person’s starting score.

Frequently asked

Can a drug be matched to my eating pattern?
Not on this evidence. The idea is reasonable, but this study analyzed 66 people across five medications with no control group, which is far too little to guide a choice.
Why are the effect sizes so large?
They are standardized changes from baseline within each group. The small groups and lack of randomization make those estimates unsuitable for comparing medications.
Who was included?
Only early responders — people who had already lost at least 5% of their weight at three months — so the findings describe people for whom treatment was already working.

Sources

  1. [1] Pineda-Wieselberg RJ, Soares AH, Napoli TF, Scalissi NM, Salles JEN (2026). Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice Nutrients. PMID 42124020

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence